Nuchal translucency and cystic hygroma colli in screening for fetal major congenital heart defects in a series of 12 910 euploid pregnancies

Ultrasound in Obstetrics and Gynecology

Volumn 35, Issue 3, 2010, Pages 273-279

  Sananes, N ^a   Guigue, V ^a   Kohler, M ^a   Bouffet, N ^a   Cancellier, M ^a   Hornecker, F ^a   Hunsinger, M C ^a   Kohler, A ^a   Mager, C ^a   Neumann, M ^a   Schmerber, E ^a   Tanghe, M ^a   Nisand, I ^a   Favre, R ^a  

^a SIHCUS CMCO Centre Medico Chirurgical et Obstetrical   (France)

Author keywords

Cardiac malformation; Cystic hygroma; Nuchal translucency; Prenatal screening

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CYSTIC LYMPHANGIOMA; ECHOGRAPHY; FEMALE; FETUS ECHOGRAPHY; FETUS HEART; GENETICS; GESTATIONAL AGE; HUMAN; INCIDENCE; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DEVELOPMENT; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; FEMALE; FETAL HEART; GESTATIONAL AGE; HEART DEFECTS, CONGENITAL; HUMANS; INCIDENCE; LYMPHANGIOMA, CYSTIC; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, PRENATAL; YOUNG ADULT;

EID: 77949643722     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.7534     Document Type: Article

References (35)

1. Hoffman JL Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16: 103-113.
2. Tegnander E, Williams W, Johansen OJ, Blaas HG, EikNes SH. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses - detection rates and outcome. Ultrasound Obstet Gynecol 2006; 27: 252-265.
3. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
4. Hyett JA, Perdu M, Sharland GK, Snijders RSM, Nicolaides KH. Increased nuchal translucency at 10 -14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 1997; 10: 242-246.
5. Ghi T, Huggon IC, Zosmer N, Nicolaides KH. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001; 18: 610-614.
6. Lopes LM, Brizot ML, Lopes MAB, Ayello VD, Schultz R, Zugaib M. Structural and functional cardiac abnormalities identified prior to 16 weeks' gestation in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2003; 22: 470-478.
7. Galindo A, Comas C, Martinez JM, Gutiérrez-Larraya F, Carrera JM, Puerto B, Borrell A, Mortera C, de la Fuente P. Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. J Matern Fetal Neonat Med 2003; 13: 163-170.
8. McAuliffe F, Hornberger LK, Winsor S, Chitayat D, Chong K, Johnson JA. Fetal cardiac defects and increased nuchal translucency thickness: a prospective study. Am J Obstet Gynecol 2004; 191: 1486-1490.
9. Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 2005; 26: 154-157.
10. Clur SA, Mathijssen IB, Pajkrt E, Cook A, Laurini RN, Ottenkamp J, Bilardo CM. Structural heart defects associated with an increased nuchal translucency: 9 years experience in a referral centre. Prenat Diagn 2008; 28: 347-354.
11. Josefsson A, Molander E, Selbing A. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination. Acta Obstet Gynecol Scand 1998; 77: 497-499.
12. Bilardo CM, Pajkrt E, de Graaf I, Mol BW, Bleker OP. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998; 11: 401-406.
13. Hyett JA, Perdu M, Sharland GK, Snijders R, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10 -14 weeks of gestation: population based cohort study. BMJ 1999; 318: 81-85.
14. Schwarzler P, Carvalho JS, Senat MV, Masroor T, Campbell S, Ville Y. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency measurement at 10 -14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 1999; 106: 1029-1034.
15. Michailidis GD, Economides DL. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001; 17: 102-105.
16. Mavrides E, Cobian-Sanchez F, Tekay A, Moscoso G, Campbell S, Thilaganathan B, Carvalho JS. Limitations of using firsttrimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 2001; 17: 106-110.
17. Orvos H, Wayda K, Kozinszky Z, Katona M, Pál A, Szabó J. Increased nuchal translucency and congenital heart defects in euploid fetuses. The Szeged experience. Eur J Obstet Gynecol Reprod Biol 2002; 101: 124-128.
18. Hafner E, Schuller T, Metzenbauer M, Schuchter K, Philipp K. Increased nuchal translucency and congenital heart defects in a low-risk population. Prenat Diagn 2003; 23: 985-989.
19. Bahado-Singh RO, Wapner R, Thom E, Zachary J, Platt L, Mahoney MJ, Johnson A, Silver RK, Pergament E, Filkins K, Hogge WA, Wilson RD, Jackson LG; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening Study Group. Elevated first trimester nuchal translucency increases the risk of congenital heart defects. Am J Obstet Gynecol 2005; 192: 1357-1361.
20. Westin M, Saltvedt S, Bergman G, Almström H, Grunewald C, Valentin L. Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16,383 fetuses. Ultrasound Obstet Gynecol 2006; 27: 632-639.
21. Bruns RF, Moron AF, Murta CG, Gonçalves LF, Zamith MM. The role of nuchal translucency in the screening for congenital heart defects. Arq Bras Cardiol 2006; 87: 307-314.
22. Muller MA, Clur SA, Timmerman E, Bilardo CM. Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies. Prenat Diagn 2007; 27: 164-169.
23. Wald NJ, Morris JK, Walker K, Simpson JM. Prenatal screening for serious congenital heart defects using nuchal translu- cency: a meta-analysis. Prenat Diagn 2008; 28: 1094-1104.
24. Simpson LL, Malone FD, Bianchi DW, Ball RH, Nyberg DA, Comstock CH, Saade G, Eddleman K, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, D'Alton ME. Nuchal translucency and the risk of congenital heart disease. Obstet Gynecol 2007; 109: 376-383.
25. Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester nuchal translucency: problems with screening the general population. 1. Br J Obstet Gynaecol 1995; 102: 381-385.
26. Herman A, Dreazen E, Herman AM, Batukan CEM, Holzgreve W, Tercanli S. Bedside estimation of Down syndrome risk during first-trimester ultrasound screening. Ultrasound Obstet Gynecol 2002; 20: 468-475.
27. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br JObstet Gynaecol 1995; 102: 957-962.
28. Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I, Weinraub Z. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol 1998; 12: 398-403.
29. Nicolaides KH, Snijders RJM, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998; 18: 519-523.
30. Cuckle H, Sehmi I. Calculating correct Down's syndrome risks. Br J Obstet Gynaecol 1999; 106: 371-372.
31. Makrydimas G, Sotiriadis A, Huggon IC, Simpson J, Sharland G, Carvalho JS, Daubeney PE, Ioannidis JP. Nuchal translucency and fetal cardiac defects: A pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol 2005; 192: 89-95.
32. Hyett J, Sonek J, Nicolaides K; FASTER Consortium. Nuchal translucency and the risk of congenital heart disease. Comment on Obstet Gynecol 2007; 109: 376-383.
33. Obstet Gynecol 2007; 109: 1455-1456; author reply 1456-1457.
34. Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH. Cystic hygromas, nuchal edema, and nuchal translucency at 11 -14 weeks of gestation. Obstet Gynecol 2006; 107: 678-683.
35. Zosmer N, Souter VL, Chan CS, Huggon IC, Nicolaides KH. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. BrJObstet Gynaecol 1999; 106: 829-833.